ニュース
Novo Nordisk aims to convince Europeans governments to pay for its obesity drug Wegovy for the most overweight or those with co-morbidities, its CEO said on Friday, emphasising both the medical ...
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy. 記事全文>>> Novo Nordisk’s New Obesity Drug Beats Wegovy Weight Loss in Early Trial ...
They were both developed by Novo Nordisk. About 180 million adults in China suffer from obesity, offering a huge market opportunity for pharmaceutical companies. Wegovy is a best-selling weight-loss ...
In March last year, the US Food and Drug Administration approved Novo Nordisk's Semaglutide for weight management in overweight individuals with heart disorders to reduce the risk of cardiovascular ...
The wildly popular obesity drugs — Wegovy developed by Novo Nordisk and Zepbound by Eli Lilly — are known as GLP-1 receptor agonists, which mimic the activity of a hormone that slows digestion and ...
Novo Nordisk <NOVOb.CO> posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する